Overview Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Status: Enrolling by invitation Trial end date: 2027-09-01 Target enrollment: Participant gender: Summary To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder Phase: Phase 3 Details Lead Sponsor: Alkermes, Inc.